In the cyclic peptide group, romidepsin, also named FK228 or depsipeptide, inhibits HDAC1 and HDAC2 and was the second HDAC inhibitor approved by the U.S. FDA to treat CTCL and PTCL. Here, HDAC9 is linked to primary cutaneous T-cell non-Hodgkin lymphoma.